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Angiogenesis in general and the vascular endothelial growth factor (VEGF) signaling axis in
particular is a validated target in renal cell carcinoma (RCC). Clear-cell carcinoma of the kid-
ney is now recognized as a malignancy that is sensitive to inhibitors of the VEGF pathway.
Treatment options for patientswithmetastatic renal cell carcinoma have evolved in dramatic
fashion over the past 6 years, and a new paradigm has developed.The cytokines interferon-
α and interleukin-2 were previously utilized for therapy, but since December 2005, six new
agents have been approved in the United States for the treatment of advanced RCC. Two
are tyrosine kinase inhibitors (TKI’s) including sunitinib and recently pazopanib, and the mul-
tikinase inhibitor sorafenib. The current review examines the evolving data with the next
generation of TKI’s, axitinib and tivozanib being developed for the treatment of advanced
RCC.These agents were synthesized to provide increased target speciﬁcity and enhanced
target inhibition.The preclinical and clinical data are examined, an overview of the develop-
ment of theseTKI’s is provided, and discussion plus speculation concerning their potential
roles as RCC therapy is provided.
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Treatment of patients with metastatic renal cell carcinoma
(mRCC) has changed dramatically during the past 5 years, and a
new paradigm has evolved. Interferon-α (INF-α) and interleukin-
2 (IL-2) were previously utilized (McDermott, 2009) but since
December 2005, a series of targeted agents have been approved
in the United States for the treatment of mRCC, including the
three multi-targeted tyrosine kinase inhibitors (TKI’s) sunitinib,
sorafenib, and pazopanib (Bukowski, 2009). The ﬁrst generation
of TKI’s included sunitinib, which has emerged as the standard of
care for treatment-naïve mRCC patients. The recent approval of
pazopanib, a second generation agent with increased speciﬁcity for
vascular endothelial growth factor (VEGF) receptors (VEGFR),
provided another option for frontline therapy. This review will
focus on several third generation TKI’s under investigation, axi-
tinib and tivozanib, and explore their current development as
therapy for mRCC. The number of agents approved within a very
short time, raises a series of questions, such as, do we need another
tyrosine kinase inhibitor for this patient population, if yes, what
should its characteristics and clinical activity be, and ﬁnally, how
should these novel agent be studied in the future?
INTRODUCTION
Clear-cell renal cell carcinoma (RCC) is the commonest subtype
of renal epithelial cancer, and accounts for over 85% of sporadic
tumors (Choueiri et al., 2003). The von Hippel–Lindau (VHL)
tumor suppressor gene located on chromosome 3p25, is silenced
in the majority of clear-cell renal tumors (Kaelin, 2007). This
gene encodes the VHL protein (p-VHL) that targets the vari-
ous hypoxia-inducible factors (HIFs) for proteolysis. HIF-α is a
regulator of the hypoxic stress response, and is a primary tar-
get of p-VHL. In hypoxic conditions or when VHL is mutated
or inactivated, p-VHL does not bind HIF-α, and levels of this
transcription factor are increased (Bukowski, 2009). The result
is increased transcription of a variety of hypoxia-inducible genes
such as VEGF, platelet-derived growth factor (PDGF), transform-
ing growth factor-α (TGF-α), epidermal growth factor receptor
(EGFR), and erythropoietin (Kaelin, 2007). VEGF plays a promi-
nent role in angiogenesis, binds to theVEGFR on endothelial cells,
and promotes proliferation and migration of these cells (Cohen
and McGovern, 2005). This makes VEGF or VEGFR attractive
targets for treatment of mRCC, a tumor characterized by VEGF
overproduction and increased vascularity. In view of this, the
development of drugs for RCC therapy has focused on these tar-
gets. TKI’s such as sunitinib and pazopanib are now approved for
treatment of these patients.
PRECLINICAL INVESTIGATIONS
The TKI’s are multi-targeted kinase inhibitors which inhibit
signaling in a variety of receptors such asVEGFR-1,-2 and -3,
platelet-derived growth factor receptors (PDGFR)-α and -β, c-
RET,macrophage colony-stimulating factor 1 (CSF-1R), FMS-like
tyrosine kinase 3 receptor (FLT3), and c-KIT (Motzer et al., 2007).
Recently, a series of small molecular third generation TKI’s includ-
ing axitinib (Hu-Lowe et al., 2008) and tivozanib (Nakamura et al.,
2006) have been developed. These agents have more restricted tar-
get spectrums, as well as higher afﬁnity for VEGFR-1, -2, and -3
when compared with sunitinib and pazopanib. The in vitro kinase
speciﬁcity of these agents is summarized in Tables 1 and 2. The
activity of these agents has been assessed against various tyrosine
kinases using either cell-free kinase assays employing recombi-
nant enzymes, or inhibition of ligand-induced phosphorylation
of growth factor receptors in a variety of cellular based assays. It
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Table 1 | Receptor tyrosine kinase inhibitory activity of selectedTKI’s – cell-free kinase assay (IC50).
TKI Axitinib (nM) Tivozanib (nM) Sunitinib (nM) Pazopanib (nM)
Reference Hu-Lowe (2008) Nakamura et al. (2006) Chow and Eckhardt (2007) Kumar et al. (2009)
VEGFR-1 ND 30 21 7
VEGFR-2 0.2 6.5 34 15
VEGFR-3 ND 15 3 2
PDGFR-β 1.6 49 75 215
c-Kit 1.7 78 40 48
FGFR-1 ND 530 437 80
IC50, inhibitory concentration 50%;TKI, tyrosine kinase inhibitor; ND, not done.
Table 2 | Receptor tyrosine kinase inhibitory activity of selectedTKI’s – inhibition ligand dependent in proliferation cell-based assay (IC50).
TKI Axitinib (nM) Tivozanib (nM) Sunitinib (nM) Pazopanib (nM)
Reference Hu-Lowe (2008) Nakamura et al. (2006) Chow and Eckhardt (2007) Kumar et al. (2009)
VEGFR-1* 0.1 (HUVEC)** 0.16 (NIH-3T3) ND ND
VEGFR-2 0.06 (HUVEC) 0.21 (HUVEC) 10 (NIH-3T3), 40 (HUVEC) 8 (HUVEC)
VEGFR-3 0.1–0.3 (VEGFR-3/PAE) 0.24 (HUVEC) ND ND
PDGFR-β 2.9 (NIH-3T3) 1.72 (NHDF) 39 (NIH-3T3) 3 (HFF)
c-Kit 0.98 (NCI-H526) 1.63 (KU812F) 1–10 (NCI-H526) 2.6 (NCI-H526)
FGFR-1 ND 299 (NHDF) 880 (NIH-3T3) ND
*TK receptor; **cell line utilized in assay; TKI, tyrosine kinase inhibitor; IC50, inhibitory concentration 50%.
is not clear which assay best reﬂects the in vivo inhibitory activity
or efﬁcacy of these TKI’s, but their utility is in demonstrating the
relative kinase speciﬁcity of the various drugs. Additionally, com-
paring the various IC50 values is problematic, since the different
assay procedures and methods were utilized.
Figure 1 illustrates the molecular structures and characteris-
tics of these two drugs. Axitinib (formerly known as AG-013736)
is a substituted indazole derivative, and was developed using
structure-based drug design technology (Kania, 2009). The result-
ing agent was a highly potent and selective inhibitor of the various
kinase domains of VEGFRs, distinguishing it from previous multi-
targeted TKIs. In vitro, axitinib inhibits the autophosphorylation
of VEGFR-1, 2, and 3 in picomolar quantities (IC50), and has
approximately a 10-fold lower potency for inhibition of PDGFR-α
and -β, and the stem-cell factor receptor KIT. Axitinib produces
in vivo inhibition of angiogenesis in various preclinical models
(Hu-Lowe et al., 2008). In various xenograft mouse models, its
antitumor activity was associated with decreased tumor vascular-
ization and blood ﬂow, and a reduction in tumor size, related to
its plasma concentrations.
Tivozanib (formerly AV-951, KRN-951) is also a highly potent
and selective VEGFR tyrosine kinase inhibitor of VEGFR-1, -2,
and -3, which inhibits angiogenesis and vascular permeability in
tumor tissues (Nakamura et al., 2006). It has antitumor effects
in human breast, colon, liver, lung, ovarian, pancreas, prostate,
brain, and RCC xenograft models (Nakamura et al., 2006; Taguchi
et al., 2008). Studies utilizing dynamic contrast-enhanced mag-
netic resonance imaging (DCE-MRI) analysis have demonstrated
the antitumor activity of this agent is associated with a signiﬁcant
reduction vascular permeability in tumors (Nakamura et al.,
2006). Both of these agents have subsequently been developed
for treatment of advanced RCC.
PHASE 1 STUDIES
AXITINIB
A phase 1 trial of axitinib (Rugo et al., 2005) was conducted in
36 patients with various solid tumors (see Table 3). Dose levels
ranged from 5 to 30mg orally twice daily. Dose-limiting toxicities
included primarily hypertension, with hemoptysis, and stomati-
tis. These were seen at the higher dose levels. The hypertension
observed was easily managed with antihypertensive medications.
Stomatitis was mild to moderate, and managed by dose reduc-
tion or drug holidays. Two patients with adenocarcinoma of the
lung receiving 20mg BID developed fatal hemoptysis. Pharma-
cokinetic studies demonstrated rapid absorption, with maximum
plasma concentrations found within 2–6 h after dosing. The dose
recommended for subsequent trialswas 5mg, twice daily, adminis-
tered while fasting. Three conﬁrmed partial responses were noted,
one in a patient with adenoid cystic carcinoma, and two patients
with mRCC. Other evidence of clinical activity was noted in three
additional patients, all of whom had reductions in tumor size that
did however, not meet RECIST criteria for a partial response. This
phase 1 trial demonstrated the potential clinical activity of axi-
tinib in advanced and refractory malignancies, and importantly,
the toxicities observed were essentially similar to those reported
with other antiangiogenic agents.
This study also demonstrated rapid absorptionof axitinibwhen
administered with food. Plasma concentrations demonstrated a
Frontiers in Oncology | Genitourinary Oncology February 2012 | Volume 2 | Article 13 | 2
Bukowski Third generation TKI’s renal cancer
FIGURE 1 | Molecular structures and chemical data for two third generation tyrosine kinase inhibitors, axitinib (Hu-Lowe et al., 2008), and tivozanib
(Gupta and Fishman, 2011).
Table 3 | Phase 1 trials third generation tyrosine kinase inhibitors (TKI’s) – axitinib and tivozanib.
TKI Axitinib (Rugo, 2005) Tivozanib (Eskens et al., 2011)
Number patients 36 41
Dose levels (mg) Six: 10–30, 20, 2.0, 5.0, 15, 5.0 Three: 1.0, 1.5, 2.0
Schedule Continuous (daily, BID) Intermittent (4/2 week schedule)
Median age (range) 57 (41–76) years 56 (28–73) years
TUMORTYPES
CR Ca 0 10
Breast 13 0
RCC 6 9
Other 17 22
Maximum tolerated dose 5.0mg BID daily 1.5mg daily day 1–28
Clinical responses: PR stable disease 3 (2 RCC patients) NS 1 (RCC patient) 55%
BID, twice daily; mg, milligram; RCC, renal cell carcinoma; CR Ca, colorectal cancer; PR, partial response; NS, not stated.
terminal half-life from 2 to 5 h. Nine patients were investigated for
the effects of food on drug levels. The rate and extent of absorption
appeared increased during fasting, (higherCmax andAUC0–24, and
a shorter Tmax), with peak concentrations seen within 1–2 h. The
investigators noted a 49% (median) increase in plasma exposure
compared to non-fasting patients.
The likely hood of drug interactions was also considered, since
in vitro studies with human liver cells demonstrated axitinib was
metabolized by conversion to glucuronide metabolites as well
as oxidation by the CYP3A4 and CYP1A2 isozymes, both P450
inducible enzymes. Potential drug interactions were investigated
in a subsequent study which assessed the effects of rifampin on
axitinib pharmacokinetics in normal volunteers (Pithavala et al.,
2010). In this trial, axitinib exposure was decreased when con-
comitantly administered with rifampin. Concomitant treatment
with axitinib and potent inducers of CYP3A4 therefore require
dose adjustment for optimal clinical efﬁcacy. The similarity of axi-
tinib pharmacokinetics in Caucasian and Japanese subjects also
supported a single starting dose and regimen for these patient
populations.
TIVOZANIB
A phase 1 and pharmacologic study of tivozanib (Eskens et al.,
2011) was conducted in 41 advanced solid tumor patients, includ-
ing nine individuals with RCC (see Table 3). Tivozanib was
administered at dose levels of 1.0, 1.5, and 2.0mg/day for 28 days
followed by a 14-day break. This intermittent schedule resembling
the one utilized for sunitinib in mRCC patients (Motzer et al.,
2007). The initial starting dose was 2.0mg/day, however, a series
of adverse events (AE’s) were noted which included grade 3 pro-
teinuria, hypertension, and ataxia. Lower dose levels were then
explored. Ten patients received 1.0mg/day, and no dose-limiting
toxicity was noted. The MTD was therefore reported as1.5mg/day
for 28 days of therapy every 6weeks. The dose-limiting toxic-
ity described was similar to other oral VEGFR inhibitors and
included hypertension, fatigue, and transaminase elevations. Clin-
ical activity was noted in 2/9 patients with metastatic RCC. One
conﬁrmed and one unconﬁrmed partial response were reported.
Additionally, 35% of patients had tumor shrinkage that did not
meet the criteria for a partial response, and 55% of patients
had stable disease. DCE-MRI analysis was also conducted in
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eight patients, and variable decreases in tumor vascularization
were noted over time. In one patient with mRCC, decreased
tumor vascularization was accompanied by some reduction in
tumor size.
Pharmacokinetic studies demonstrated slow absorption of
tivozanib after single ormultiple doses,withmaximal plasma levels
observed between 2 and 24 h. Signiﬁcant inter-patient variabil-
ity was found, and the possibility of enterohepatic recirculation
was suggested. The mean half-life of tivozanib was 112 h (range
31–233 h).
PHASE 2 TRIALS: RENAL CELL CARCINOMA
AXITINIB
Three single arm phase 2 trials of axitinib were conducted in
previously treated patients with metastatic RCC. These included
either cytokine refractory or treatment refractory individuals. The
results of these studies are summarized in Tables 4–6. Axitinib was
administered at a starting dose of 5.0mg twice daily (BID) orally
with food, and was escalated in a step-wise fashion to 7mg BID,
then to 10mg BID, in the absence of toxicity greater than grade
2 for a continuous 2week period, and absence of hypertension
(deﬁned as two blood pressure measurements of >150/90mmHg
taken in the clinic>1 h apart).
The ﬁrst study accrued 52 cytokine refractory patients (Rixe
et al., 2007). The results of this trial were remarkable, with an
overall response rate (ORR) of 44% (2/23 CR’s), a stable dis-
ease rate (>8weeks) of 42%, a median progression free sur-
vival (PFS) of 15.7months, and median overall survival (OS) of
29.9months. 53.2% of patients had their initial axitinib dose esca-
lated to>5.0mg BID. A second phase 2 trial was conducted in 62
patients with refractory mRCC who had previously failed therapy
with sorafenib, but also may have received prior chemotherapy,
cytokines, and/or other targeted therapies such as sunitinib, beva-
cizumab, and temsirolimus. In this trial, axitinib dose escalation
Table 4 | Axitinib phase 2 trials – refractory metastatic RCC.
Author(s) Rini et al. (2009) Rixe et al. (2007) Tomita et al. (2011)
Number patients 52 62 64
prior therapy Sorafenib±other* Cytokines Cytokines
Axitinib dose/schedule 5.0mg BID daily, dose escalation 5.0mg BID daily, dose escalation 5.0mg BID daily, dose escalation
% ORR (CR/PR) 44% (2/21) 23% (0/14) 50% (0/32)
Median PFS (months) 15.7 (95% CI, 8.4–23.4) 7.4 (95% CI, 6.7–11.0) 11.0 (95% CI, 9.2–12.0)
Median OS (months) 29.9 (95% CI, 20.3–NE) 13.6 (95% CI, 8.4–18.8) NS
*Previous therapy may have also included bevacizumab, sunitinib, temsirolimus, cytokines, chemotherapy, and other miscellaneous agents.
BID, twice daily; NE, not estimable; NS, not stated; PFS, progression free survival; OS, overall survival; ORR, overall response rate.
Table 5 | Phase 2 axitinib trials – adverse events.
Author(s) Rini et al. (2009) Rixe et al. (2007) Tomita et al. (2011)
Previous therapy Sorafenib refractory±other* (N =62) Cytokine refractory (N =52) Cytokine refractory (N =64)
Axitinib dose/schedule 5.0mg BID, dose escalation 5.0mg BID, dose escalation 5.0mg BID, dose escalation
Adverse event All Gr (%) ≥ Gr 3 (%) All Gr (%) ≥ Gr 3 (%) All Gr (%) ≥ Gr 3 (%)
Diarrhea 60 10 61 15 64 5
Hypertension 58 15 45 16 84 70
Fatigue 52 8 77 16 48 5
Nausea 44 0 44 7 25 0
Dysphonia NS Ns 37 0 53 0
Hand–foot syndrome NS NS 36 16 75 22
Anorexia 35 2 48 0 36 5
Weight loss 27 0 31 5 30 3
Dyspepsia 23 0 NS NS NS NS
Vomiting 21 0 32 5 16 0
Headache NS NS 29 0 23 0
Arthralgia NS NS 27 3 19 3
BID, twice daily; Gr, grade.
*Previous therapy may also have included bevacizumab, sunitinib, temsirolimus, cytokines, chemotherapy, and/or other.
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Table 6 | Phase 2 axitinib trials – laboratory abnormalities.
Author(s) Rini et al. (2009) Rixe et al. (2007) Tomita et al. (2011)
Grade (Gr) All Gr (%) ≥ Gr 3 (%) All Gr (%) ≥ Gr 3 (%) All Gr (%) ≥ Gr 3 (%)
Anemia 64.3 0 NS NS 3.0 2.0
Thrombopenia 19.6 0 NS NS 11.0 2.0
Neutropenia 10.9 0 NS NS 6.0 2.0
Erythrocytosis NS NS 3.2 NS 3.0 0
Proteinuria NS NS 27.4 NS 58.0 9.0
TSH increased 17.7 NS NS NS 31.0 0
ALT NS NS NS NS 23.0 3.0
AST NS NS NS NS 23.0 2.0
Alk phosphatase NS NS NS NS 17.0 0
LDH NS NS NS NS 13.0 0
NS, not stated.
was reported in 11.5% of patients, who received >5.0mg BID.
The ORR was reported as 22.6% (95% CI, 12.9–35.0), with sta-
ble disease in 18%. The median PFS was 7.6months, and median
OS 13.6months. The ORR in the 33 patients receiving >5.0mg
BID was 21%. The investigators suggested higher doses may have
been associated with a higher frequency of tumor regression. A
third phase 2 study was conducted in Japan, and included cytokine
refractory patients. Sixty-four individuals received axitinib (start-
ing dose: 5mg BID) with dose escalation in 8%. An ORR of 50%
was reportedwith amedianPFSof 11.0months. In summary, these
studies provided evidence of efﬁcacy in refractory RCC patients,
with median PFS values similar or in excess of those reported in
the phase 3 trials of either sunitinib or pazopanib (Motzer et al.,
2007; Sternberg et al., 2010). With axitinib monotherapy, the most
common AE’s reported included hypertension, fatigue, and gas-
trointestinal toxicity (Table 5). The majority of AE’s were ≤grade
2, and demonstrate that the continuous administration of this axi-
tinib dose appears to have acceptable toxicity, and is compatible
with chronic therapy.
An interesting association between diastolic blood pressure and
clinical outcome has been suggested by retrospective reviews of
these trials. Hypertension is common following administration of
a third generation TKI such as axitinib. It is generally easily man-
aged with standard antihypertensive agents. In multiple tumor
types, across, the occurrence of diastolic hypertension ≥90mmHg
during axitinib treatment was associated with increased efﬁcacy,
including OS (Rini et al., 2011a). A pooled analysis of data from
the axitinib phase 2 renal cancer trials (N = 114) explored the rela-
tionship between pharmacokinetics, diastolic hypertension, and
clinical efﬁcacy (Rixe et al., 2009). Both diastolic hypertension
≥90mmHg andAUC appear to be independent predictors of clin-
ical efﬁcacy, with clinical responses also associated with increasing
axitinib plasma exposure. These observations are of interest, and
are being examined in a prospective manner. The possibility that
hypertension is not merely related to higher axitinib drug levels,
but itself is a biomarker of efﬁcacy exists.
The laboratory abnormalities reported in these studies are sum-
marized in Table 6. In the two trials conducted in the United States
and Western Europe, minimal hematologic toxicity was reported,
with treatment-related proteinuria recorded in 2/17 patients by
Rixe et al. (2007). In contrast, proteinuria was reported in a much
higher frequency by Tomita et al. (2011) in the Japanese popu-
lation studied, with 28% developing levels ≥2.0 g/24 h requiring
treatment interruption and/or discontinuation.
TIVOZANIB
A preliminary report of the single phase 2 trial of tivozanib in
mRCC patients is available. The study utilized a random discon-
tinuation design (Bhargava et al., 2010), with 272 patients pre-
dominantly from Eastern Europe treated. Tivozanib was adminis-
tered at a dose of 1.5mg daily for 3weeks, followed by a 1-week
rest (3/1 week schedule). This open-label study phase involved
16weeks of initial therapy, atwhich timepatientswere randomized
dependent upon the degree of tumor regression noted: (1) Group
A: ≥25% tumor regression – continue open-label tivozanib; (2)
Group B: <25% change from baseline – randomized in a dou-
ble blind fashion to continue tivozanib or placebo for 12weeks;
(3) Group C: ≥25% tumor growth – stop therapy. The patient
population included untreated (53.7%) as well as refractory indi-
viduals, as well as patients with clear cell (83.1%) and non-clear
cell (16.9%) histology. This design therefore was somewhat dif-
ferent that the phase 2 RTD pazopanib trial (Hutson et al., 2010),
and not only included a signiﬁcant proportion of treatment-naïve
patients, but also patients with non-clear cell histology.
In the RTD portion of this trial, 111 patients with SD were
randomized to either tivozanib or a placebo (Nosov et al.,
2010). The median PFS was longer for patients continuing
tivozanib (n = 58; 12.1months) compared to the placebo group
(n = 53; 6.3months).A signiﬁcantly greater proportion of patients
remained progression free after 12weeks of on the tivozanib arm
(p = 0.003). In the placebo group, 26/29 patients with PD on
placebo, 26 crossed back to open-label tivozanib. Of this group,
24/26 had either SD or a response.
The data for all patients entered as well as the various patient
subsets is summarized in Table 7.The median treatment duration
was reported as 8.5months (range 0.03–23.8months). Of interest,
the median PFS for all patients was reported as 11.8months. It is
not clear how the RTD design impacted these data. The various
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subset analyses demonstrate increased efﬁcacy for the patientswith
clear cell histology and prior nephrectomy. The reported toxicity
proﬁle of tivozanib is summarized in Table 8. The AE’s reported
are similar to those seen with other VEGFR inhibitors, including
hypertension in 50% of individuals. Tivozanib associated hepatic
toxicity was modest.
In summary, the results of this trial demonstrate tivozanib has
signiﬁcant efﬁcacy in RCC with an acceptable AE proﬁle. The
study design was not optimal, and the RTD approach was prob-
ably unnecessary for an agent expected to be active in RCC. It is
also unclear how limiting patient entry to predominantly Eastern
Europe affected the evaluation of efﬁcacy and toxicity. Additional
studies to further delineate the clinical activity of tivozanib are
now required.
PHASE 3 TRIALS: METASTATIC RCC
Phase 3 trials examining either axitinib or tivozanib in patients
with mRCC have been conducted. The overall study designs were
similar, and utilized a common active comparator arm, sorafenib.
Table 7 | Phase 2 tivozanib randomized discontinuation trial (Bhargava
et al., 2010; Bhargava and Robinson, 2011).
Patient group Patient
no.
Median PFS (months) ORR
(%)
All patients 272 11.8 (95% CI; 253–450 days) 27
HISTOLOGIC SUBSETS
Clear cell 226 12.5 29
Non-clear cell 46 6.7 17
PRIORTHERAPY (CLEAR CELL)
Treatment naïve 77 14.3 43
≥1 Prior therapy 99 15.9 23
PRIOR NEPHRECTOMY
Yes 199 14.1 30
No 73 8.2 18
Prior nephrectomy+
clear cell carcinoma
176 14.8 32
CI, conﬁdence interval; ORR, overall response rate.
Table 8 | Phase 2 trial tivozanib – adverse events and laboratory
abnormalities (Bhargava et al., 2010; Bhargava and Robinson, 2011).
Adverse event All grades (%) Grade 1/2 (%) Grade 3/4 (%)
Hypertension 50.0 41 9.0
Dysphonia 22.0 22.0 0
Asthenia 13.0 11.0 2.0
Diarrhea 12.0 11.0 1.0
Fatigue 8.0 7.0 1.0
Rash 6.0 5.0 1.0
Cough 6.0 6.0 0
ALT elevation 28.0 26.0 2.0
AST elevation 26.0 <1.0 26.0
Total bilirubin 8.0 8.0 <1.0
Patient populations were however different, and included treat-
ment refractory patients in the phase 3 axitinib trial, in con-
trast to the inclusion of cytokine refractory and treatment-naïve
patients in the phase 3 tivozanib trial (see Figure 2). The pri-
mary endpoint in each trial was PFS determined by independent
review.
PHASE 3 AXITINIB TRIAL (AXIS)
The pivotal Phase 3 mRCC Study (Rini et al., 2011b) investigating
axitinib was a randomized comparative trial vs the approved TKI,
sorafenib (Figure 2). Patients with advanced mRCC after failure of
one prior systemic ﬁrst-line regimen were eligible. Prior therapy
may have included one or more of the following agents: sunitinib,
bevacizumab, temsirolimus, or cytokine(s). Patients also had his-
tologically or cytologically conﬁrmed RCC with a component of
clear-cell subtype, with measurable disease per RECIST criteria
(version 1.0). Patients were randomized in a 1:1 ratio to axitinib
(5mg BID administered orally with food), or sorafenib (400mg
BID administered orally without food). In patients receiving axi-
tinib, who tolerated therapy, dose escalation to 7mg BID and then
to a maximum of 10mg BID was permitted. The trial design inves-
tigated whether treatment could increase the median PFS from
5months (sorafenib cohort), to 7months for axitinib therapy. A
sample size of 650 patients with 409 events (progressive disease
or death), based on 90% power (one-sided log-rank test, p value
0.025) was estimated.
A total of 723 patients were randomized to either axi-
tinib (n = 361) or sorafenib (n = 362). The median PFS was
6.7months for axitinib treated patients, compared to 4.7months
for sorafenib group (hazard ratio 0.665; 95% CI 0.544, 0.812;
one-sided p< 0.0001). When the four prespeciﬁed subgroups
of patients were examined (Table 9), the majority of individu-
als had previously received either sunitinib (54%) or cytokines
(35%). The major difference in PFS was noted in the cytokine
refractory cohort, and in the sunitinib refractory group, the differ-
ence in PFS was <1.5months (4.8 vs 3.4months). The groups
previously treated with bevacizumab or temsirolimus were of
limited size.
Secondary endpoints in this study included ORR and survival.
Partial responses assessed by an independent review commit-
tee, were more frequent in axitinib treated patients. The median
response durations reportedwere 11.0 (95%CI; 7.4,not estimable)
months for the axitinib group, and 10.6 (95%CI; 8.8, 11.5)months
for sorafenib treated patients. The survival data were described as
immature (Rini et al., 2011b), however, an interim analysis pre-
sented at the December 7, 2011 meeting of the FDA ODAC com-
mittee demonstrated overlapping survival curves (FDA, 2011),
with the median OS demonstrating no differences. The ﬁnal sur-
vival analysis however, is pending. Potential issues confounding
the survival data include crossover from sorafenib to axitinib,
however this was not permitted. A second issue involved con-
tinuation of treatment following disease progression. Fifty of
one hundred eighty-seven (26.7%) axitinib patients compared to
74/214 (34.6%) sorafenib treated patients continued the respective
TKI≥ 28 days following PD.
The axitinib AE proﬁle appeared similar to other small mol-
ecule VEGF pathway inhibitors. Selected AE’s reported in the
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FIGURE 2 | Phase 3 pivotal trial (AXIS andTIVO-1) designs for studies of axitinib or tivozanib vs sorafenib.
Table 9 | Phase 3 trial axitinib versus sorafenib – efficacy (FDA, 2011; Rini et al., 2011b).
Patient group PFS – months (95% CI) HR (95% CI) for progression/death pValue
Axitinib (N =361) Sorafenib (N =362)
All patients 6.7 (6.3, 8.6) 4.7 (4.6, 5.6) 0.665 (0.544, 0.812) <0.0001
PREVIOUSTHERAPY
Cytokines 12.3 (10.1, 13.9) (N =50) 6.5 (6.3, 8.3) (N =69) 0.47 (0.32, 0.68) <0.0001
Sunitinib 4.8 (4.5, 6.4) (N =194) 3.4 (2.8, 4.7) (N =195) 0.74 (0.57, 0.96) 0.011
Bevacizumab 4.2 (2.8, 6.5) (N =29) 4.7 (2.8, 6.7) (N =30) 1.147(0.57, 2.32) 0.64
Temsirolimus 10.1 (1.5, 10.2) (N =12) 5.3 (1.5, 10.1) (N =12) 0.51 (0.14, 1.87) 0.143
RESPONSE (%)
Partial 19% (N =70) 9% (N=34)
SD≥20 weeks 27% (N =96) 21% (N=77)
ORR 19% (15.4, 23.9) 9% (6.6, 12.9) 0.0001
Median OS (mos) NR (15.9, NE) (deaths=113) 18.9 (18.0, NE) (deaths=110) 1.008 (0.77, 1.31) 0.53
PFS, progression free survival; CI, conﬁdence interval; N, number; SD, stable disease; ORR, overall response rate; OS, overall survival.
AXIS study are summarized in Table 10. These include com-
mon AEs such as diarrhea, nausea, hypertension, fatigue, and
cutaneous toxicity, as well as uncommon events such as arter-
ial and venous thrombosis, gastrointestinal perforation, bleeding,
hypothyroidism,proteinuria, and the reversible posterior leukoen-
cephalopathy syndrome. In general, higher rates of gastrointestinal
events, fatigue, asthenia, hypertension, hypothyroidism (19 vs
9%), and dysphonia (32 vs 14%) were seen in patients receiv-
ing axitinib compared to sorafenib. In contrast, axitinib treated
patients had lower rates of dermatologic AEs. Hepatic toxicity
produced by axitinib appears less compared to other to VEGF
pathway small molecule inhibitors, with a lower degree of liver
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Table 10 | Phase 3 trial axitinib versus sorafenib (AXIS) – selected AE’s
and laboratory abnormalities (Rini et al., 2011b).
Patient group Axitinib (N =359) Sorafenib (N =355)
Grade (Gr) All Gr (%) ≥ Gr 3 (%) All Gr (%) ≥ Gr 3 (%)
Diarrhea 55.0 11.0 53.0 7.0
Hypertension 40.0 16.0 29.0 11.0
Fatigue 39.0 11.0 32.0 5.0
Anorexia 34.0 5.0 29.0 4.0
Nausea 32.0 3.0 22.0 1.0
Palmar–plantar
erythrodysesthesia
27.0 5.0 51.0 16.0
Anemia 35.0 <1.0 52.0 4.0
Hemoglobin
elevation
10.0 NS <1.0 NS
Neutropenia 6.0 1.0 8.0 1.0
Thrombopenia 15.0 <1.0 14.0 0
Creatinine increase 55.0 0 41.0 <1.0
Proteinuria 11.0 3.0 7.0 2.0
N, number patients; NS, not stated.
enzyme elevation. In the current trial, treatment was discontin-
ued because of toxicity in 14/359 (4%) patients receiving axitinib
and 29/355 (8%) sorafenib patients. Diarrhea and hyperten-
sion accounted for the majority of dose modiﬁcations in the
axitinib cohort, while sorafenib patients more often required
dose modiﬁcations for palmar–plantar erythrodysesthesia and
diarrhea.
Patient questionnaires (FKSI and FSKI-DRS) were completed
by over 90% of subjects. The estimated means in the FKSI-15 and
FKSI-DRS were similar between the two treatment arms. Overall,
axitinib treatment resulted in patient reported outcomes compara-
ble to sorafenib in second-line mRCC patients (Cella et al., 2011).
A composite time to deterioration endpoint (death, progression,
worsening of FSKI), showed a 25% risk reduction for axitinib vs
sorafenib (p = 0.0001; Rini et al., 2011b).
An application for axitinib approval as therapy for a broad
mRCC indication has been submitted to the FDA, and is cur-
rently under review. Several additional studies investigating the
efﬁcacy of axitinib in mRCC patients are in progress. A phase 2
double blind randomized trial in treatment-naïve patients inves-
tigating the effects of dose escalation on safety and efﬁcacy is
underway (NCT00835978, 2011). A second phase 3 trial in 447
treatment naïve, or sunitinib and/or cytokine refractory patients
comparing the efﬁcacy of axitinib and sorafenib is also in progress
(NCT00920816,2011). These studieswill provide additional infor-
mation on the safety and efﬁcacy of axitinib, prospective data
on the efﬁcacy of dose escalation, and additional information on
outcomes in the refractory and treatment-naïve patient subsets.
PHASE 3 TIVOZANIB TRIAL (TIVO-1)
Figure 2 also illustrates the design of the pivotal TIVO-1 trial
in mRCC patients (NCT01030783, 2011). As in the AXIS trial,
an active comparator arm employing sorafenib was utilized.
The patients eligible however, include individuals who have not
received prior VEGF therapy, therefore essentially comprising a
treatment naïve as well as a cytokine refractory group. Addition-
ally, prior nephrectomy and an ECOG performance status of 0–1
are required. The primary endpoint is PFS, with secondary end-
points of OS, ORR, and quality of life. A total of 500 patients have
been randomized (1:1) to receive either sorafenib or tivozanib.
This study is ongoing, accrual has been completed, and ﬁnal data
analysis is pending.
SUMMARY AND CONCLUSION
The currently available targeted agents provide signiﬁcant clinical
beneﬁt for patients with mRCC, however, these agents also pro-
duce signiﬁcant off-target toxicities that may limit their effective-
ness. The development of additional VEGFR TKIs with improved
potency and selectivity therefore may provide more effective and
better tolerated treatment options. Additionally, the possibility
that combinations may be easier to develop utilizing the more
selective third generation TKI’s exists.
1. Do we need another TKI for metastatic RCC? The currently
available therapeutic optionshave clearly improvedpatient out-
comes as measured by the surrogate PFS. Improvement of OS
has been more difﬁcult to demonstrate, possibly because of
study design and the inclusion of crossover treatment options
in many of the trials. The third generation of TKI’s now under
study, are still utilizing PFS as the primary endpoint, how-
ever, the study designs involve the active comparator sorafenib.
Examination of the two pivotal trials which compare either
axitinib or tivozanib to sorafenib suggest the following:
a. Studies in the treatment-naïve population to determine if
the increased in vitro potency and selectivity for VEGFR
will translate into increased efﬁcacy are required. Compar-
isons with existing TKI’s such as sunitinib or pazopanib
are necessary to provide this type of evidence. If increased
effectiveness cannot be demonstrated, than the issue of tol-
erability and toxicity should be critically addressed. Again,
this will require comparative studies with current standards
of care. The currently completed studies have not addressed
these issues. The TIVO-1 trial will provide information on
the treatment-naïve patient population,but this is a subset of
the study population,with sorafenib, an agent never demon-
strated in a phase 3 trial to improve outcomes for mRCC
patients, utilized as the comparator. Similarly, data on the
efﬁcacy of axitinib in the treatment-naïve patient subset will
be available, but the comparator remains sorafenib.
b. Studies in refractory patient populations to determine if
this third generation of TKI’s can provide clinical beneﬁt
for patients when utilized as sequential therapy following
either VEGF inhibitor therapy or cytokines. From the avail-
able data, it is clear these two patient populations are very
different clinically in their responses to second-line agents.
(1) Cytokine refractory or intolerant mRCC: this patient
population has become increasingly uncommon as the
utilization of TKI’s for treatment-naïve patients has
been adopted. In recent phase 3 trials, this is clearly
demonstrated with 46% of patients in the phase 3
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Table 11 | AXIS and RECORD 1 trials – results in sunitinib refractory patients.
Trial AXIS (axitinib vs sorafenib; Rini et al., 2011b) Record 1 (everolimus vs placebo; Motzer et al., 2010; Figlin, 2011)
No. patients 361 366 277 139
Previous sunitinib 194 195 124 60
Previous sunitinib+ sorafenib 0 0 72 36
PFS (months) 4.8 3.4 3.9 1.8
HR 0.74 (95% CI, 0.57–0.96) HR 0.34 (95% CI, 0.23–0.51)
ORR (%) 11.3% 7.7% NA NA
Response duration (months) 11.0 11.1 NA NA
NA, not available; HR, hazard ratio; CI, conﬁdence interval; PFS, progression free survival; ORR, overall response rate.
pazopanib trial and 35% of patients in the phase 3 axi-
tinib trial classiﬁed as cytokine refractory. Additionally,
the frequency of initial cytokine therapy will vary from
country to country, and in the United States, initial
cytokine therapy is increasingly less common. There-
fore, the relevance of including this group as a subset of
patients in future clinical trials has been questioned.
In the TIVO-1 trial, this patient group will also be
prominently represented.
(2) TKI refractorymRCC: this patient group is themost fre-
quent refractory population encountered in the United
States. The RECORD 1 trial investigating everolimus vs
a placebo clearly demonstrated an oral mTOR inhibitor
can improve PFS compared to supportive care alone
(Motzer et al., 2008). This agent is therefore a rea-
sonable comparator in TKI refractory patient studies.
In the AXIS trial, 54% of patients had received suni-
tinib as frontline therapy, representing the majority
of individuals in this trial. In Record 1, 211 patients
had received one prior TKI, including 124 who had
only received sunitinib. In this trial, patients may also
have received other agents including cytokines or beva-
cizumab, therefore the patients subsets in these two
studies are potentially different. The number of patients
and their outcome in the RECORD 1 trial receiving only
sunitinib as frontline therapy are not available. These
two trials in the TKI refractory patient subset are con-
trasted in Table 11. An analysis of the RECORD 1 data
has demonstrated that patients receiving prior sunitinib
therapy had a poorer prognosis compared to those
receiving sorafenib. The timing of therapy is however
not directly addressed by this analysis. The results of
these two trials does permit even indirect comparisons
of which agent is best utilized in the second line setting.
Both study results demonstratemodest effects on PFS in
the refractory disease setting, and as described, the char-
acteristics of each treatment population are different.
Direct prospective comparisons in a well-deﬁned pop-
ulation are therefore necessary. In the absence of such a
trial, sequential use of agents with differentmechanisms
of action seems a reasonable alternative.
In summary, in view of the lack of prospective comparative
data in frontline patients, limited information on the mechanisms
of resistance and progression in RCC patients receiving TKI’s, and
prospective data inwhich comparisons are limited, treatment deci-
sions, and recommendations should be based on available level
1 evidence. The third generation of TKI’s appears potentially
interesting with efﬁcacy similar or better than existing agents,
and acceptable AE proﬁles. Demonstration of improved or less
toxicity requires randomized studies utilizing appropriate com-
parisons and patient populations. The possibility that the third
generation of TKI’s can be utilized in combination approaches in
view of their apparent improved safety proﬁles is an important
consideration. Finally, the lack of Cooperative group interest or
participation in such trials is a major concern limiting the fur-
ther development of the knowledge base delineating therapy for
advanced RCC.
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